Menu

A screenshot of an Eli Lilly letter

Eli Lilly defended its policy requiring covered entities to report 340B claims data for in-house pharmacy utilization in a late-January letter to HRSA.

Lilly Defends 340B In-House Pharmacy Claims Data Requirements, 340B Health and Other Providers Push Back

February 3, 2026 Luke Zarzecki 340B Report Views

Drugmaker Eli Lilly defended its newly implemented policy requiring covered entities to report 340B claims data for in-house pharmacy utilization [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

If you are not yet a paid subscriber, please Subscribe now

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Luke Zarzecki

Navigating the Evolution of 340B in 2026

Providers Raise Concerns Over Manufacturer Handling of 340B Claims Under the IRA